Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a98cb1b197f761c87cd3caf32bc247e2 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_31e39ac5e469ab81a8e8b1bdfc769d5c http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a60e155dbf2bc7018b089998be8af74d |
classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-24 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-94 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-156 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-106 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6886 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-241 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-513 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7072 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-24 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-505 |
filingDate |
2012-08-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
grantDate |
2016-06-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ef7b16a4b89637f6668b7a760c7c2902 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9a02205528ff168008a5b0fbe2d2641a |
publicationDate |
2016-06-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
US-9371380-B2 |
titleOfInvention |
Antitumor agent and therapeutic effect prediction method for patients with KRAS-mutated colorectal cancer |
abstract |
This invention provides a method for predicting a therapeutic effect of chemotherapy that uses an antitumor agent comprising α,α,α-trifluorothymidine and 5-chloro-6-(1-(2-iminopyrrolidinyl)methyl)uracil hydrochloride at a molar ratio of 1:0.5 on a colorectal cancer patient,n the method comprising: (1) detecting the presence or absence of KRAS gene mutation in a biological sample obtained from the patient; and (2) predicting that the patient is likely to sufficiently respond to the chemotherapy, when KRAS gene mutation is detected in Step (1). |
isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2021177850-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10456399-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2018338976-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10960004-B2 |
priorityDate |
2011-08-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |